Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

40.78 +1.16 (+2.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharma

< Previous 1 2 3 4 5 6 Next >
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
NASDAQ:AMPH, an undervalued stock with good fundamentals.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. 
Via Chartmill
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Via ACCESSWIRE
Delving into NASDAQ:AMPH's Growth Prospects.
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? 
Via Chartmill
Earnings Outlook For Amphastar Pharma
Via Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. 
Via Chartmill
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
Via ACCESSWIRE
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to. 
Via InvestorPlace
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued.
For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:AMPH.
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
NASDAQ:AMPH is not too expensive for the growth it is showing.
Looking for growth without the hefty price tag? Consider NASDAQ:AMPH. 
Via Chartmill
Why NASDAQ:AMPH is Poised for High Growth.
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition
Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... 
Via Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
Cassava Sciences Stock Continues Showing Rising Relative Strength
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Should you consider NASDAQ:AMPH for growth investing?
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
Why NASDAQ:AMPH qualifies as a high growth stock.
Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). 
Via Chartmill
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
3 Reasons Why Amphastar Is a Great Growth Stock
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great... 
Via Talk Markets
3 Stocks at the Forefront of Medical Innovation
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. 
Via InvestorPlace
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.